4//SEC Filing
TAYTON-MARTIN HELEN KATRINA 4
Accession 0001104659-21-031733
CIK 0001621227other
Filed
Mar 2, 7:00 PM ET
Accepted
Mar 3, 9:01 PM ET
Size
6.0 KB
Accession
0001104659-21-031733
Insider Transaction Report
Form 4
TAYTON-MARTIN HELEN KATRINA
Chief Operating Officer
Transactions
- Exercise/Conversion
Ordinary Shares with a nominal value of GBP0.001 per share
2021-03-03$0.16/sh+1,785,000$280,245→ 1,800,000 total
Footnotes (3)
- [F1]The ordinary shares whose purchase is reported on this line were obtained from the exercise of share options that were granted on March 20, 2015. The ordinary shares continue to be held by the Reporting Person.
- [F2]The price reported in Column 4 of $0.157 per ordinary share is derived from the option purchase price paid on March 3, 2021 of GBP0.112 per ordinary share.
- [F3]The 1,800,000 ordinary shares reported in Column 5 include 1,785,000 ordinary shares reported in Column 4 as well as 15,000 ordinary shares held by the Reporting Person. The ordinary shares reported in Column 5 represent solely the ordinary shares beneficially owned by the Reporting Person. Additionally, the Reporting Person holds options covering an aggregate of 9,703,672 ordinary shares of the Issuer. Ordinary shares may be represented by American Depositary Shares (ADSs) with each ADS representing six ordinary shares.
Documents
Issuer
Adaptimmune Therapeutics PLC
CIK 0001621227
Entity typeother
Related Parties
1- filerCIK 0001661780
Filing Metadata
- Form type
- 4
- Filed
- Mar 2, 7:00 PM ET
- Accepted
- Mar 3, 9:01 PM ET
- Size
- 6.0 KB